PPT-Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

PARAMESWARAN HARI MD MEDICAL COLLEGE OF WISCONSIN Support Acknowledgement This activity has been made possible through an unrestricted educational grant from Spectrum Pharmaceuticals 2 Accreditation Information. Andrzej . J. . Jakubowiak, MD, PhD. Director, Myeloma Program. Director, Clinical Trials Subcommittee, MMRC. Loyola University, May 16, 2015. What is Multiple Myeloma?. Malignant cells grow mostly in bones and secrete monoclonal antibodies . Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Multiple myeloma .The management of the newly diagnosed patient . Bone. Marrow. G,A,E. Plasma cell. Virgin B cell. Lymphoblast. Lymphoplasmacyte. Plasma blast. Germinal Center. SOMATIC. Pre-B cell. IgM. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Friday, October 5, 2012. Transplant . Center Growth and. Management Best Practices. 1. . Institutional Vision and Commitment. 2. Dedicated Team. 3. Aggressive Clinical Style. 4. . Patient and “Family” Centered Care. Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Cynthia S. Herrington, MD. Associate Professor of Surgery. Keck School of Medicine. University of Southern California. Optimizing Lung Transplant Outcomes. Holy SRTR . International practices and outcomes and where the pitfalls exist --ISHLT. Myeloma Symposium 9/29/2018. Aric Hall, MD – Assistant Professor – UW School of Medicine & Public Health. Disclosures. I have no significant conflicts of interest to disclose. . I have no financial relationship with any institution profiting from pharmaceutical sales, diagnostic testing, or any type of medical technology. . Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.